ALMOTRIPTAN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H25N3O2S
Molecular Weight	335.464
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N3CCCC3)C=C2

InChI

InChIKey=WKEMJKQOLOHJLZ-UHFFFAOYSA-N

InChI=1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C17H25N3O2S
Molecular Weight	335.464
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021001s010s011lbl.pdf | https://www.drugs.com/cdi/almotriptan.html

Almotriptan is a triptan drug for the treatment of migraine headaches. Almotriptan is marketed under the trade name Axert. Almotriptan is used for treating acute migraine headaches with or without aura (eg, dark spots, flashing lights, wavy lines). Almotriptan binds with high affinity to 5-HT1D, 5-HT1B, and 5-HT1F receptors. Almotriptan has weak affinity for 5-HT1A and 5-HT7 receptors, but has no significant affinity or pharmacological activity at 5-HT2, 5-HT3, 5-HT4, 5-HT6; alpha or beta adrenergic; adenosine (A1, A2); angiotensin (AT1, AT2); dopamine (D1, D2); endothelin (ETA, ETB); or tachykinin (NK1, NK2, NK3) binding sites.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 1b (5-HT1b) receptor 45 Target ID: CHEMBL1898 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021001s008s009lbl.pdf	Agonist 2752
Serotonin 1d (5-HT1d) receptor 53 Target ID: CHEMBL1983 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021001s010s011lbl.pdf	Agonist 2752
Serotonin 1f (5-HT1f) receptor 15 Target ID: CHEMBL1805 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021001s010s011lbl.pdf	Agonist 2752

Conditions

Condition	Modality	Targets	Highest Phase	Product
Migraine 107 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021001s010s011lbl.pdf	Primary		Approved 8583	AXERT Approved Use Almotriptan tablets, USP are a 5HT1B/1D receptor agonist (triptan) indicated for: •Acute treatment of migraine attacks in adults with a history of migraine with or without aura (1.1) •Acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine with or without aura, and who have migraine attacks usually lasting 4 hours or more (1.1) Important Limitations: •Use only after a clear diagnosis of migraine has been established (1.2) •In adolescents age 12 to 17 years, efficacy of almotriptan tablets on migraine-associated symptoms was not established (1.2) •Not intended for the prophylactic therapy of migraine (1.2) •Not indicated for the treatment of cluster headache (1.2) 1.1 Acute Treatment of Migraine Attacks Adults Almotriptan tablets, USP are indicated for the acute treatment of migraine attacks in patients with a history of migraine with or without aura. Adolescents Age 12 to 17 Years Almotriptan tablets are indicated for the acute treatment of migraine headache pain in patients with a history of migraine attacks with or without aura usually lasting 4 hours or more (when untreated). 1.2 Important Limitations Almotriptan tablets should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with almotriptan tablets, the diagnosis of migraine should be reconsidered before almotriptan tablets are administered to treat any subsequent attacks. In adolescents age 12 to 17 years, efficacy of almotriptan tablets on migraine-associated symptoms (nausea, photophobia, and phonophobia) was not established. Almotriptan tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine [see Contraindications (4.7) Launch Date 2001

C_max

Value	Dose	Co-administered	Analyte	Population
52.6 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12723463	12.5 mg single, oral dose: 12.5 mg route of administration: Oral experiment type: SINGLE co-administered:		ALMOTRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
312 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12723463	12.5 mg single, oral dose: 12.5 mg route of administration: Oral experiment type: SINGLE co-administered:		ALMOTRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
3.5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021001s015lbl.pdf	unknown, oral		ALMOTRIPTAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.1 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12723463	12.5 mg single, oral dose: 12.5 mg route of administration: Oral experiment type: SINGLE co-administered:		ALMOTRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
65% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021001s015lbl.pdf	unknown, oral		ALMOTRIPTAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
3 mg single, intravenous Dose: 3 mg Route: intravenous Route: single Dose: 3 mg Sources: https://pubmed.ncbi.nlm.nih.gov/12463724	healthy, 19-33 years Health Status: healthy Age Group: 19-33 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/12463724	Sources: https://pubmed.ncbi.nlm.nih.gov/12463724
10 mg single, subcutaneous Highest studied dose Dose: 10 mg Route: subcutaneous Route: single Dose: 10 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11768838	unhealthy, 42 years (range: 18-72 years) Health Status: unhealthy Age Group: 42 years (range: 18-72 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/11768838	Sources: https://pubmed.ncbi.nlm.nih.gov/11768838
12.5 mg multiple, oral Recommended Dose: 12.5 mg Route: oral Route: multiple Dose: 12.5 mg Sources: https://pubmed.ncbi.nlm.nih.gov/12005273	unhealthy, 42 years (range: 18-72 years) Health Status: unhealthy Age Group: 42 years (range: 18-72 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/12005273	Disc. AE: Chest pain, Electrocardiogram QTc interval prolonged... AEs leading to discontinuation/dose reduction: Chest pain (0.9%) Electrocardiogram QTc interval prolonged (0.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/12005273
100 mg multiple, oral Highest studied dose Dose: 100 mg Route: oral Route: multiple Dose: 100 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert_prntlbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert_prntlbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert_prntlbl.pdf
200 mg single, oral Highest studied dose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert_prntlbl.pdf	healthy, adult Health Status: healthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert_prntlbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert_prntlbl.pdf

AEs

AE	Significance	Dose	Population
Electrocardiogram QTc interval prolonged	0.7% Disc. AE	12.5 mg multiple, oral Recommended Dose: 12.5 mg Route: oral Route: multiple Dose: 12.5 mg Sources: https://pubmed.ncbi.nlm.nih.gov/12005273	unhealthy, 42 years (range: 18-72 years) Health Status: unhealthy Age Group: 42 years (range: 18-72 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/12005273
Chest pain	0.9% Disc. AE	12.5 mg multiple, oral Recommended Dose: 12.5 mg Route: oral Route: multiple Dose: 12.5 mg Sources: https://pubmed.ncbi.nlm.nih.gov/12005273	unhealthy, 42 years (range: 18-72 years) Health Status: unhealthy Age Group: 42 years (range: 18-72 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/12005273

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946	inhibitor 2438	substrate 1388 inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2A6 879 CYP2B6 926 CYP2C19 2057 CYP2E1 1060 CYP3A4/5 296 CYP4A9/11 35	FMO3 77 CYP3A4/5 91 CYP1A2 1197 CYP2C8 810 CYP2C19 1119

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert_pharmr_P1.pdf Page: 49.0	no
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert_pharmr_P1.pdf Page: 49.0	no
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert_pharmr_P1.pdf Page: 49.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert_pharmr_P1.pdf Page: 49.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert_pharmr_P1.pdf Page: 49.0	no
CYP2E1 1146	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert_pharmr_P1.pdf Page: 49.0	no
CYP3A4/5 357	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert_pharmr_P1.pdf Page: 49.0	no
CYP4A9/11 35	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert_pharmr_P1.pdf Page: 49.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert_pharmr_P1.pdf Page: 49.0	weak [Ki 87 uM]

Drug as victim

Target	Modality	Activity
CYP1A2 1197	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert_pharmr_P1.pdf Page: 27.0	yes
CYP2C19 1119	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert_pharmr_P1.pdf Page: 27.0	yes
CYP2C8 810	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert_pharmr_P1.pdf Page: 27.0	yes
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert_pharmr_P1.pdf Page: 27.0	yes
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert_pharmr_P1.pdf Page: 27, 49	yes
CYP3A4/5 91	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert_pharmr_P1.pdf Page: 27.0	yes
FMO3 77	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert_pharmr_P1.pdf Page: 27.0	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:520985	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:520985
ChemicalBook	CB7716603	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7716603
eMolecules	5852303	https://www.emolecules.com/cgi-bin/more?vid=5852303
ZINC	ZINC000000018087	http://zinc15.docking.org/substances/ZINC000000018087

PubMed

Title	Date	PubMed
Correlation between lipophilicity and triptan outcomes.	2005-01	15663606
Evaluating triptan usage: a rebuttal.	2004-10	15447710
Pharmacokinetics and safety of oral almotriptan in healthy male volunteers.	2004-10	15386481
[Meta-analysis of triptan treatment in migraine].	2004-09	15552863
Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project).	2004-09	15531016
TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management.	2004-09	15285768
Meta-analysis of oral triptans.	2004-08	15265060
A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point.	2004-07-02	15228377
Involvement of 5-HT1B receptors in triptan-induced contractile responses in guinea-pig isolated iliac artery.	2004-07	15185063
Patterns of use of triptans and reasons for switching them in a tertiary care migraine population.	2004-06-24	15209687
Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms.	2004-06	15154851
Almotriptan improves response rates when treatment is within 1 hour of migraine onset.	2004-04	15109355
Triptans and chest symptoms: the role of pulmonary vasoconstriction.	2004-04	15030540
A comparison of the pharmacokinetics and tolerability of the anti-migraine compound almotriptan in healthy adolescents and adults.	2004-04	15030538
Cost considerations of acute migraine treatment.	2004-03	15012668
Gateways to clinical trials.	2004-02-28	14988742
Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease.	2004-02-26	14987333
Evaluating triptan usage.	2004-02	14756865
Clinical benefits of early triptan therapy for migraine.	2004	15595991
Clinical profile and practice experience of almotriptan.	2004	15595990
What do patients want from acute migraine treatment?	2004	15595989
Migraine pathophysiology and its clinical implications.	2004	15595988
Gateways to clinical trials.	2003-12	14735233
Early intervention with almotriptan improves sustained pain-free response in acute migraine.	2003-11-25	14629242
Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours.	2003-11-14	14613361
Cost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraine.	2003-11	14693315
Migraine: diagnosis and management.	2003-09-27	14511196
Almotriptan versus rizatriptan in patients with migraine in Spain.	2003-08-02	12890128
A review of the clinical efficacy and tolerability of almotriptan in acute migraine.	2003-07	12831340
Interaction between ketoconazole and almotriptan in healthy volunteers.	2003-04	12723463
Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan.	2003-04	12642466
Safety profile of the triptans.	2003-03	12904112
Gateways to clinical trials. March 2003.	2003-03	12731460
A case of carotidynia with response to almotriptan.	2003-03	12603374
[Almotriptan in the treatment of migraine attacks in clinical practice: results of the TEA 2000 observational study].	2003-02-19	12590376
A review of the effects of almotriptan and other triptans on clinical trial outcomes that are meaningful to patients with migraine.	2003-02	12749502
Current perspectives on effective migraine treatments: are small clinical differences important for patients?	2003	15071619
Almotriptan: an effective and well-tolerated treatment for migraine pain.	2003	15071618
Newer formulations of the triptans: advances in migraine management.	2003	14524731
Gateways to clinical trials.	2002-12	12616965
Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers.	2002-12	12463724
Efficacy and safety of almotriptan malate for migraine.	2002-11-15	12455302
Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.	2002-10	12383060
New medications show promise for migraine sufferers.	2002-10	12382492
New drugs 2002, part III.	2002-07	12352871
Gateways to Clinical Trials. June 2002.	2002-06	12168506
Almotriptan, a new anti-migraine agent: a review.	2002	12353056
Spotlight on rizatriptan in migraine.	2002	12269863
Comparative aspects of triptans in treating migraine.	2001	12739316
Almotriptan: pharmacological differences and clinical results.	2001	12463281

Patents

Sample Use Guides

In Vivo Use Guide

Adults and adolescents age 12 to 17 years: 6.25 mg or 12.5 mg single dose; may repeat after 2 hours if headache returns; benefit of second dose in patients who have failed to respond to first dose has not been established; maximum daily dose 25 mg Patients with hepatic or severe renal impairment: 6.25 mg starting dose; maximum daily dose 12.5 mg

Route of Administration: Oral

In Vitro Use Guide

In vitro Almotriptan showed selectivity of action for migraine-related human arteries (i.e. contractile EC(50) of 30 and 700 nm for meningeal and temporal arteries, respectively), whereas the effect on arteries supplying blood to the brain was lower.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:07:05 GMT 2025` Edited by `admin` on `Mon Mar 31 18:07:05 GMT 2025`
Record UNII	1O4XL5SN61
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ALMOTRIPTAN

Official Name

English

LAS-31416

Preferred Name

English

Almotriptan [WHO-DD]

Common Name

English

1-[[[3-[2-(Dimethylamino)ethyl]indol-5-yl]methyl]sulfonyl]pyrrolidine

Systematic Name

English

ALMOTRIPTAN [USAN]

Common Name

English

almotriptan [INN]

Common Name

English

LAS31416

Code

English

ALMOTRIPTAN [VANDF]

Common Name

English

ALMOTRIPTAN [MI]

Common Name

English

PYRROLIDINE, 1-(((3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-5-YL)METHYL)SULFONYL)-

Systematic Name

English

NSC-760092

Code

English

Classification Tree Code System Code

WHO-VATC

QN02CC05